UTUC therapy yields high rate of disease eradication, durability

Article

In this video, Seth P. Lerner, MD, discusses the OLYMPUS Trial of intracavitary UGN-101 (mitomycin gel; Jelmyto) in patients with low-grade upper tract urothelial carcinoma.

In patients with low-grade upper tract urothelial carcinoma, treatment with intracavitary UGN-101 (mitomycin gel; Jelmyto) resulted in a high rate of disease eradication that was found to be durable in a majority of patients, results of the OLYMPUS Trial showed. In this interview, senior author Seth P. Lerner, MD, discusses the study’s efficacy and tolerability data and where this therapy fits into the current treatment paradigm. Lerner was interviewed by Urology Times® Editorial Consultant J. Brantley Thrasher, MD. Disclosure: The OLYMPUS Trial was funded by UroGen Pharma.

Related Videos
Dr. Camilo Arenas-Gallo in an interview with Urology Times
Dr. Larissa Rodriguez in an interview with Urology Times
Dr. Michael Lutz in an interview with Urology Times
Dr. Nour Abdallah in an interview with Urology Times
Dr. Ashley Ross in an interview with Urology Times
Dr. Bilal Chughtai in an interview with Urology Times
Dr. Adam Murphy in an interview with Urology Times
Related Content
© 2024 MJH Life Sciences

All rights reserved.